The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides

European Journal of Pharmaceutical Sciences

Volumn 76, Issue , 2015, Pages 149-155

  Zhi, Duo ^a   Feng, Pan Feng ^a   Sun, Jia Liang ^a   Guo, Fengfeng ^a   Zhang, Rui ^a   Zhao, Xin ^a   Li, Bao Xin ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Key Lab of Biopharmaceut Eng   (China)

Author keywords

Azithromycin (AZM); Berberine (BBR); Cardiac toxicity; Clarithromycin (CLR); Cytochrome P450 (CYP); hERG

Indexed keywords

AZITHROMYCIN; BERBERINE; CLARITHROMYCIN; CYTOCHROME P450 3A; MACROLIDE; POTASSIUM CHANNEL HERG; ANTIINFECTIVE AGENT; CYP3A2 PROTEIN, RAT; CYTOCHROME P450 3A INHIBITOR; ERG1 POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CARDIOTOXICITY; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INHIBITION; DRUG METABOLISM; EMBRYO; ENZYME ACTIVITY; HALF-ACTIVATION VOLTAGE; HUMAN; HUMAN CELL; IC50; KINETICS; LIVER MICROSOME; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; RECOVERY TIME CONSTANT; REPOLARIZATION; SLOPE FACTOR; STEADY STATE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HEART DISEASE; HEK293 CELL LINE; MEMBRANE POTENTIAL; METABOLISM; PATHOPHYSIOLOGY; RISK ASSESSMENT; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BERBERINE; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG SYNERGISM; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART DISEASES; HEK293 CELLS; HUMANS; MALE; MEMBRANE POTENTIALS; MICROSOMES, LIVER; MYOCYTES, CARDIAC; POTASSIUM CHANNEL BLOCKERS; RATS; RATS, WISTAR; RISK ASSESSMENT; TRANSFECTION;

EID: 84929312132     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.05.009     Document Type: Article

References (38)

1. F. Affuso, V. Mercurio, V. Fazio, and S. Fazio Cardiovascular and metabolic effects of Berberine World J. Cardiol. 2 2010 71 77
2. T. Akiyoshi, M. Ito, S. Murase, M. Miyazaki, F.P. Guengerich, K. Nakamura, K. Yamamoto, and H. Ohtani Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants Drug Metab. Pharmacokinet. 28 2013 411 415
3. B. Al-Qallaf, D.B. Das, D. Mori, and Z. Cui Modelling transdermal delivery of high molecular weight drugs from microneedle systems Philos. Trans. Series A Math. Phys. Eng. Sci. 365 2007 2951 2967
4. G. Berecki, J.G. Zegers, A.O. Verkerk, Z.A. Bhuiyan, B. de Jonge, M.W. Veldkamp, R. Wilders, and A.C. van Ginneken HERG channel (dys)function revealed by dynamic action potential clamp technique Biophysical J. 88 2005 566 578
5. W. Chatuphonprasert, N. Nemoto, T. Sakuma, and K. Jarukamjorn Modulations of cytochrome P450 expression in diabetic mice by berberine Chemico-biological Interact. 196 2012 23 29
6. J. Ducroq, R. Printemps, S. Guilbot, J. Gardette, C. Salvetat, and M. Le Grand Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies J. Pharmacol. Toxicol. Meth. 56 2007 159 170
7. G. Friedrich, T. Rose, and K. Rissler Determination of testosterone metabolites in human hepatocytes. I. Development of an on-line sample preparation liquid chromatography technique and mass spectroscopic detection of 6beta-hydroxytestosterone J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 784 2003 49 61
8. F.P. Guengerich Cytochrome P-450 3A4: regulation and role in drug metabolism Annu. Rev. Pharmacol. Toxicol. 39 1999 1 17
9. Y. Guo, F. Li, X. Ma, X. Cheng, H. Zhou, and C.D. Klaassen CYP2D plays a major role in berberine metabolism in liver of mice and humans Xenobiotica; the fate of foreign compounds in biological systems 41 2011 996 1005
10. Y. Guo, Y. Chen, Z.R. Tan, C.D. Klaassen, and H.H. Zhou Repeated administration of berberine inhibits cytochromes P450 in humans Eur. J. Clin. Pharmacol. 68 2012 213 217
11. C.A. Karle, V.A. Kreye, D. Thomas, K. Rockl, S. Kathofer, W. Zhang, and J. Kiehn Antiarrhythmic drug carvedilol inhibits HERG potassium channels Cardiovascular Res. 49 2001 361 370
12. A.B. Ke, M.J. Zamek-Gliszczynski, J.W. Higgins, and S.D. Hall Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies Clin. Pharmacol. Therap. 95 2014 473 476
13. B.X. Li, B.F. Yang, J. Zhou, C.Q. Xu, and Y.R. Li Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes Acta Pharmacol. Sin. 22 2001 125 131
14. M.F. Nilsson, and W.S. Webster Effects of macrolide antibiotics on rat embryonic heart function in vitro Birth Defects Res. Part B Develop. Reprod. Toxicol. 101 2014 189 198
15. P.J. Petersen, P. Labthavikul, C.H. Jones, and P.A. Bradford In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis J. Antimicrobial Chemotherapy 57 2006 573 576
16. M.P. Purdon, and L.D. Lehman-McKeeman Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites J. Pharmacol. Toxicol. Meth. 37 1997 67 73
17. W.A. Ray, K.T. Murray, K. Hall, P.G. Arbogast, and C.M. Stein Azithromycin and the risk of cardiovascular death New England J. Med. 366 2012 1881 1890
18. A. Rodriguez-Menchaca, T. Ferrer-Villada, J. Lara, D. Fernandez, R.A. Navarro-Polanco, and J.A. Sanchez-Chapula Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels J. Cardiovascular Pharmacol. 47 2006 21 29
19. M.C. Sanguinetti, and M. Tristani-Firouzi HERG potassium channels and cardiac arrhythmia Nature 440 2006 463 469
20. T. Sasano, K. Ueda, M. Orikabe, Y. Hirano, S. Kawano, M. Yasunami, M. Isobe, A. Kimura, and M. Hiraoka Novel C-terminus frameshift mutation, 1122fs/147, of HERG in LQT2: additional amino acids generated by frameshift cause accelerated inactivation J. Mol. Cell. Cardiol. 37 2004 1205 1211
21. A. Schramm, I. Baburin, S. Hering, and M. Hamburger HERG channel inhibitors in extracts of Coptidis rhizoma Planta Med. 77 2011 692 697
22. S.J. Stanat, C.G. Carlton, W.J. Crumb Jr., K.C. Agrawal, and C.W. Clarkson Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel Mol. Cell. Biochem. 254 2003 1 7
23. M. Sun, Y. Tang, T. Ding, M. Liu, and X. Wang Inhibitory effects of celastrol on rat liver cytochrome P450 1A2, 2C11, 2D6, 2E1 and 3A2 activity Fitoterapia 92 2014 1 8
24. H. Svanstrom, B. Pasternak, and A. Hviid Use of azithromycin and death from cardiovascular causes New England J. Med. 368 2013 1704 1712
25. W. Tang, and R.A. Stearns Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions Curr. Drug Metab. 2 2001 185 198
26. M.B. Thomsen, J.D. Beekman, N.J. Attevelt, A. Takahara, A. Sugiyama, K. Chiba, and M.A. Vos No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block British J. Pharmacol. 149 2006 1039 1048
27. P. Thurner, A. Stary-Weinzinger, H. Gafar, V.S. Gawali, O. Kudlacek, J. Zezula, K. Hilber, S. Boehm, W. Sandtner, and X. Koenig Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine J. Pharmacol. Exp. Therap. 348 2014 346 358
28. W.A. Volberg, B.J. Koci, W. Su, J. Lin, and J. Zhou Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics J. Pharmacol. Exp. Therap. 302 2002 320 327
29. X. Wang, and J.H. Yeung Effects of Salvia miltiorrhiza extract on the liver CYP3A activity in humans and rats Phytotherapy Res.: PTR 25 2011 1653 1659
30. S. Wang, Y. Li, L. Xu, D. Li, and T. Hou Recent developments in computational prediction of HERG blockage Curr. Topics Med. Chem. 13 2013 1317 1326
31. H.H. Yu, K.J. Kim, J.D. Cha, H.K. Kim, Y.E. Lee, N.Y. Choi, and Y.O. You Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus J. Med. Food 8 2005 454 461
32. J. Yun, M. Han, C. Song, S.H. Cheon, K. Choi, and H.G. Hahn Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors Bioorg. Med. Chem. Lett. 24 2014 3234 3237
33. Y. Zhang, Z. Dong, L. Jin, K. Zhang, X. Zhao, J. Fu, Y. Gong, M. Sun, B. Yang, and B. Li Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression Biochem. Pharmacol. 85 2013 59 68
34. D. Zhang, D.B. Das, and C.D. Rielly Microneedle assisted micro-particle delivery from gene guns: experiments using skin-mimicking agarose gel J. Pharm. Sci. 103 2014 613 627
35. K. Zhang, D. Zhi, T. Huang, Y. Gong, M. Yan, C. Liu, T. Wei, Z. Dong, B. Li, and B. Yang Berberine induces hERG channel deficiency through trafficking inhibition Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 34 2014 691 702
36. E. Zitron, C.A. Karle, G. Wendt-Nordahl, S. Kathofer, W. Zhang, D. Thomas, S. Weretka, and J. Kiehn Bertosamil blocks HERG potassium channels in their open and inactivated states British J. Pharmacol. 137 2002 221 228
37. E. Zitron, C. Kiesecker, E. Scholz, S. Luck, R. Bloehs, S. Kathofer, D. Thomas, J. Kiehn, V.A. Kreye, H.A. Katus, W. Schoels, and C.A. Karle Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone Naunyn-Schmiedeberg's Arch. Pharmacol. 370 2004 146 156
38. G.Y. Zuo, Y. Li, J. Han, G.C. Wang, Y.L. Zhang, and Z.Q. Bian Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA) Molecules 17 2012 10322 10330